The estimated Net Worth of Ronit Satchi Fainaro is at least $1.9 Milion dollars as of 15 June 2024. Ronit Fainaro owns over 21,108 units of Teva- Pharmaceutical Industries stock worth over $1,585,455 and over the last 6 years he sold TEVA stock worth over $0. In addition, he makes $310,424 as Independent Director at Teva- Pharmaceutical Industries.
Ronit has made over 6 trades of the Teva- Pharmaceutical Industries stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 21,108 units of TEVA stock worth $379,100 on 15 June 2024.
The largest trade he's ever made was exercising 21,108 units of Teva- Pharmaceutical Industries stock on 15 June 2024 worth over $379,100. On average, Ronit trades about 6,748 units every 113 days since 2018. As of 15 June 2024 he still owns at least 88,277 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Ronit Fainaro stock trades at the bottom of the page.
Professor Ronit Satchi-Fainaro serves as Independent Director of the Company. Prof. Satchi-Fainaro has been a professor at Tel Aviv University since 2015, where she has served as Head of the Cancer Research and Nanomedicine Laboratory since 2006, Chair of the Department of Physiology and Pharmacology at the Sackler Faculty of Medicine since 2014, Chair of The Kurt and Herman Lion Cathedra in Nanosciences and Nanotechnologies since 2017 and a member of the Preclinical Dean’s Committee since 2015. She served as President of The Israel Controlled Release Society from 2010 to 2014. In 2003, she was appointed Instructor in Surgery at Children’s Hospital in Boston and Harvard Medical School, where she has been a Visiting Professor since 2005. Prof. Satchi-Fainaro also serves as a consultant to several biotech and pharmaceutical companies, and is a member of the scientific advisory board of the Blavatnik Center for Drug Discovery, The Israel Cancer Association and Vall d’Hebron University Hospital Foundation—Research Institute. She is also a member of several editorial boards of scientific journals. Prof. Satchi-Fainaro received her B.Pharm. from the Hebrew University in Jerusalem in 1995 and her Ph.D. in Polymer Chemistry and Cancer Nanomedicine from the University of London in 1999.
As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Ronit Fainaro at Teva- Pharmaceutical Industries is $310,424. There are 18 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Ronit Fainaro is 47, he's been the Independent Director of Teva- Pharmaceutical Industries since 2018. There are 27 older and 1 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Ronit's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks oraz Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: